SCHEMIC brain injury has been shown to lead to neuronal injury and glial damage, in part due to the excessive extracellular accumulation of the EAAs glutamate and aspartate. 4 The most abundant free amino acid in the mammalian brain is L-glutamic acid, but almost all brain L-glutamate is stored intracellularly against a concentration gradient. 8, 12, 30 The concentration of EAAs in the brain is carefully regulated by influx and efflux across the BBB, brain metabolism, and neuronal/glial transport. 1, 27 Transport of amino acids across the brain microcirculation plays an important role in the maintenance of low levels of EAAs in the brain under physiological conditions and during ischemia. 25, 27 In addition to its physiological role in the regulation of CBF, adenosine has been shown to function as an endogenous neuroprotector during prolonged ischemia and reperfusion. 29 Adenosine has been shown in hippocampal slices to inhibit the release of aspartate and glutamate compounds, neutrophil generation of superoxide anions, and leukocyteendothelial cell interactions. 5 In the present study, we hypothesized a novel physiological action of adenosine on the microcirculation and EAA transport. We used an in vitro preparation of whole, mounted, perfused, penetrating arterioles (50-60 m in diameter), which have an integrity approximating that of brain capillaries. Our study demonstrated that abluminal adenosine attenuated the net vector transport of glutamate and aspartate from the blood to the brain. This endogenous regulation of EAA transport across brain arterioles by adenosine has not been previously demonstrated.
form an area of constriction 40 to 45 m wide, whereas the perfusion pipette was tapered to a tip measuring 30 to 35 m in diameter. The vessel was pulled up into one end of a holding pipette, and a central cannulating pipette was inserted into the lumen of the vessel. The vessel wall was sealed by creating a vacuum between the inner surface of the holding pipette and the outer surface of the cannulating pipette. The other end of the vessel was also cannulated to permit continuous perfusion of fluid through the vessel. The downstream end of the vessel was connected to a manometer used to set intraluminal pressure via an outflow reservoir. The upstream end was connected to a microinfusion pump (Bioanalytical Systems, Inc., West Lafayette, IN) for intraluminal fluid perfusion. A fluid reservoir, which was pressurized by the manometer, was inserted into the fluid path between the vessel and pump by means of a three-way liquid switch. The upstream pressure was monitored using a pressure transducer (Gould Inc., Cleveland, OH). The cannulated vessel was observed on a video monitor (Panasonic, Inc., Tokyo, Japan) with the aid of a video camera (Dage-MTI Inc., Michigan City, IN), and the lumen diameter was measured with the aid of a video dimension analyzer (Colorado Video, Inc., Boulder, CO). The isolated vessels prepared in this way are viable, and share many of the properties of in vivo cerebral vessels. 14 After cannulation, the intraluminal pressure was initially set at 60 mm Hg. The system was checked for leaks both by visual inspection and by monitoring the upstream pressure. Vessels with documented leaks due to poor cannulation or branches were discarded. Before the development of spontaneous physiological tone, the "passive" vessel diameter was measured. The bath solution was changed to one not containing albumin, and the bath temperature was raised to 37˚C. The inflow lines were primed for 2.5 minutes at 30 l/minute and the isolated arteriole was perfused at a constant rate of 4 l/minute. This rate of intraluminal perfusion was chosen to avoid any flow-mediated effect on the vessel diameter. 23 A nonpermeant dye, phenol red, was perfused along with the perfusate to check for leaky vessels or poor cannulation that might otherwise have been undetected by visual inspection and pressure monitoring. The bath medium was continuously circulated with the aid of a roller pump. After an equilibration period lasting approximately 30 minutes, viable arterioles exhibited vasomotion and contracted spontaneously. The control diameter was measured after the development of a steady physiological tone. Only vessels that contracted to less than 70% of the passive diameter were used for the BBB experiment.
The Protocols
A syringe containing albumin, the desired trace compounds, and phenol red replaced the first syringe and the vessel was perfused intraluminally at a rate of 4 l/minute after priming. Serial 10-minute samples were then collected from the extraluminal bath medium as it circulated at 1 ml/minute. The volume of bath medium collected was kept constant. The bath equilibrated after 30 minutes and a baseline amount of extravasation was established. To determine the effect of the proposed agents on vasoactivity, the vessel diameter was measured continuously during each 10-minute sample period. The amount of extravasation of 14 C-or 3 H-labeled intraluminal compounds was measured by double-labeled liquid scintillography. Permeability values were adjusted for changes in diameter, unless otherwise indicated, by dividing the permeability values by ⌬dl 2 (in which l represents the length of the isolated vessel and ⌬d the change in vessel diameter).
Drugs and Solutions
Sodium nitroprusside was used as an NO donor. The SNP was dissolved in sterile water and subsequent dilutions were made using buffered saline. Adenosine was dissolved in sterile water as a 1-mM stock solution. Subsequent dilutions were made using buffered saline and the pH was adjusted to 7.3. Adenosine, SNP (sodium dinitroferricyanide dehydrate), phenol red (phenolsulfonphthalein sodium salt), bovine serum albumin (fraction V), cold L-aspartate, and nystatin (all purchased from Sigma Chemical Co., St. Louis, MO) were used in the experiment. Poly(adenylic acid) (Boehringer Mannheim Corp., Indianapolis, IN) was dissolved in buffered saline at a concentration of 10 Ϫ6 M, and the pH was adjusted to 7.3. The poly(A) consists of an average of 10,000 adenylate units, but only one adenosine moiety at its 3Ј end. 
Statistical Analysis
Data in the text and figures are presented as the percentage of change in diameter or in permeability over the values measured before drug administration (mean Ϯ standard deviation). Statistical analysis was performed using a two-tailed t-test of unequal variance. A probability value less than 0.05 was considered significant. Glutamate, aspartate, adenosine, and the blood-brain barrier 
Results

Effects of Adenosine, SNP, and Poly(A) on Vessel Diameter
Adenosine (10 Ϫ6 M) and an NO donor, SNP (10 Ϫ5 M applied extraluminally), significantly dilated the vessels over baseline values by 24 Ϯ 4% and 22 Ϯ 0.75%, respectively (mean Ϯ standard deviation, seven vessels; p Ͻ 0.01; Fig. 2A ). These concentrations of adenosine and SNP were chosen because they induced a similar degree of vasodilation after extraluminal application. Following extraluminal application, the changes in vessel diameter persisted and did not abate during a prolonged (40-minute) exposure to adenosine or SNP.
To confirm that the action of adenosine on vessel diameter is extraluminal, a poly(A) polymer (10 Ϫ6 M) was applied intraluminally (five vessels) and there was no significant effect on vessel diameter (change of 1.05 Ϯ 0.64%). Each poly(A) polymer, an adenosine analog with an adenosine moiety at its 3Ј end, consists of an average of 10,000 adenylate units and, therefore, cannot penetrate the BBB.
Effects of Adenosine, SNP, and Poly(A) on the Permeability of the BBB
We monitored the extravasation of the radioactive tracers to determine changes in BBB permeability to [ 
Characterization of Stereospecific Transport for EAAs
H]D-aspartate was applied intraluminally to the isolated vessel preparation (five vessels), after which the extravasate was sampled and the radioactivity assessed. There was a significant percentage of increase in extraluminal counts per minute in the abluminal effluent after application of [
Effects of SNP and Adenosine on Stereospecific EAA Transport
To determine the effects of SNP and adenosine on stereoselective aspartate transport, the isolated vessels were exposed to SNP (10 Ϫ5 M; seven vessels) or adenosine (10 Ϫ6 M; seven vessels), which was applied extraluminally ( 
Response of Various Doses of Adenosine on Vessel Diameter and BBB Permeability
Extraluminal application of adenosine, at doses ranging from 10 Ϫ8 to 10 Ϫ3 M, resulted in an incremental effect on vessel diameter (five vessels; Fig. 5 ). With regard to the permeability of the BBB, extraluminal application of adenosine ranging from 10 Ϫ8 to 10 Ϫ4 M had no significant effect on the permeability of the BBB to [ 
Role of Adenosine Receptors in the Control of BBB Permeability
To determine whether adenosine's effect on [ 
Discussion
We can summarize the main findings of this study as follows. 1) Adenosine, at physiological and at low pathophysiological concentrations (10 Ϫ7 and 10 Ϫ6 M, respectively), caused a decrease in the net extravasation of intravascular aspartate and glutamate (EAAs) into the brain. This finding contrasts with the effects of SNP, which caused a breakdown in the BBB and led to an increase in extravasation of
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Glutamate, aspartate, adenosine, and the blood-brain barrier EAAs. At high concentrations (10 Ϫ3 M), adenosine also caused a breakdown in the BBB. 2) Theophylline, a nonselective adenosine receptor antagonist, inhibited the effect of adenosine on the extravasation of aspartate and glutamate, indicating that the effect of adenosine is receptor mediated. 3) Pretreatment with theophylline (5 ϫ 10 Ϫ6 M) had no effect on the diameter of resting arterioles, but caused a net increase in the efflux of [ 3 H]L-aspartate. This suggests that endogenous baseline levels of adenosine regulate tonic glutamate and aspartate extravasation. 4) Intraluminal application of poly(A) (10 Ϫ6 M), a large adenosine analog confined to the lumen by the endothelium, 22 had no significant effect on [ 3 H]L-aspartate transport, demonstrating that adenosine's effect on the transport of EAAs occurs on the abluminal surface of penetrating cerebral arterioles. To our knowledge, this is the first physiological demonstration of stereoselective, modulatory transport across a mammalian microvascular segment maintained in vitro. Moreover, these observations are novel in their demonstration of a potential physiological role for adenosine in the regulation of the BBB.
Intracerebral arterioles are the most distal resistance vessels of the cerebral circulation. These vessels consist of a single layer of endothelium surrounded by smooth muscle and thin adventitia. 6 Isolated penetrating cerebral vessels are amenable for intraluminal and extraluminal drug application and express many of the phenotypical features of the in vivo BBB. 3, 28 These features include the presence of complex, interendothelial tight junctions, a restricted permeability to polar solutes, and stereospecific transport (Laspartate compared with D-aspartate). The penetrating cerebral arterioles (diameter 50-60 m) used in this study provide the closest approximation to brain microvascular endothelial cells at the capillary level, and are extremely useful in the investigation of the effect of vasodilation on permeability and transport. As demonstrated in the present study, these vessels provide a BBB to sucrose and amino acids.
Transport across the BBB occurs by either a transcellular or paracellular route. The transcellular pathway involves specialized carrier-mediated transport mechanisms at the luminal and abluminal surfaces of the endothelium. The paracellular pathway, in contrast, is limited by tight junctions between endothelial cells and is controlled by cyclic adenosine monophosphate-, cyclic guanosine monophosphate-and protein kinase C-dependent mechanisms. 11, 15, 19 Efflux studies in which the radiolabeled isomer of aspartate was used, have confirmed the results of in vitro studies on rat brain endothelial cells. 31 These data revealed that biologically active L-aspartate accumulated to a greater extent than the D-isomer. The biologically active L-enantiomer is selectively transported across the endothelium by the acidic amino acid transport system (transcellular route). In contrast, the D-isomer of aspartate is transported across the BBB through the paracellular route. In rats, D-aspartate has been shown to be excluded by the endothelium, as predicted by its unfavorable oil/water partition coefficient.
Effects of Adenosine on EAA Transport and BBB Integrity
The role of adenosine on EAA transport in the permeability of brain microvessels is unknown. In the present study, concentrations of adenosine in the physiological range (10 Ϫ7 M) and in the low pathophysiological range (10 Ϫ6 M) decreased the net extravasation of aspartate and glutamate from vessels into the brain (influx). Moreover, theophylline (5 ϫ 10 Ϫ6 M), a nonselective A 1 and A 2 adenosine receptor antagonist, inhibited the effects of adenosine on aspartate and glutamate extravasation This suggests that the effect of adenosine on EAA transport is receptor mediated and probably occurs by means of the A 1 or A 2 adenosine receptor subtype. At the concentration used in the present study, theophylline is well below concentrations expected to affect phosphodiesterase inhibition or catecholamine and calcium activation, 21 but it significantly inhibits adenosine (10 Ϫ6 M)-induced vasodilation of intraparenchymal arterioles in vitro 22 and of pial arterioles in vivo. 21 Theophylline also significantly blocks the response of pial arteriolar blood flow and CBF responses to hypoxia. 21 As in previous studies, 21, 22 theophylline had no effect on the diameter of the resting arteriole. Prior to the exogenous application of adenosine, however, extraluminal theophylline (5 m) caused a significant net increase in the efflux of Resting endogenous concentrations of adenosine in the brain have been demonstrated to be 10 Ϫ7 M. 20 At this concentration, adenosine decreased the net vectorial transport (that is, efflux) of EAAs, indicating that adenosine's effect is a physiological phenomenon, which may play a role in regulating EAA concentration. A physiological role for adenosine in regulating the levels of EAAs is further suggested by the observation that pretreatment with theophylline caused a net increase in the efflux of EAAs, in the absence of an effect of adenosine on the diameter of the resting vessel.
In pathophysiological states (for example, hypoxia, 32 ischemia, 33 and seizures 35 ), adenosine concentrations are rapidly elevated to 10 Ϫ6 M and, with time, reach concentrations as high as 10 Ϫ4 M or 10 Ϫ3 M. [32] [33] [34] As demonstrated in the present study, at 10 Ϫ6 M, adenosine results in a net decrease in EAA influx into the brain, thus serving to protect FIG. 6 . Graph depicting adenosine receptor blockade. Theophylline (Theo; 5 ϫ 10 Ϫ6 M; five vessels), a competitive A 1 and A 2 adenosine receptor blocker, was applied extraluminally both alone (arrow marks drug administration) and during exposure to adenosine (10 Ϫ6 M). Theophylline alone has no effect on BBB permeability to sucrose; however, the drug causes a significant increase in the net efflux of L-aspartate either alone or in combination with adenosine (*p Ͻ 0.05; **p Ͻ 0.02). This increased efflux is opposite to the effects of adenosine alone, which decreases the net efflux of EAA from the vessel into the brain. the brain. With a higher concentration (for example, 10 Ϫ3 M), however, adenosine causes a breakdown in the BBB and no longer plays a neuroprotective role. Instead, at such a high concentration, adenosine contributes to the well-recognized disruption of the integrity of the BBB, which is observed following severe ischemia, hypoxia, and seizures.
Intraluminal application of adenosine must first penetrate the endothelial monolayer before interacting with extraluminal adenosine receptors and causing vasodilation. 22 Having demonstrated that adenosine's actions were receptor mediated, we sought to determine if the effects were luminal, abluminal, or both. In response to an intraluminal application of a large adenosine analog, poly(A) (10 Ϫ6 M), we observed no significant effect on vessel diameter, BBB integrity in response to sucrose, or [ 3 H]L-aspartate transport. The concentration of poly(A) used in the present study has been shown to activate adenosine receptors potently and elicits significant vasodilation when applied extraluminally. 22 The lack of an effect of intraluminally applied poly(A), coupled with the effect of extraluminally applied adenosine on EAA transport, indicates that adenosine's effect on EAA transport occurs on the abluminal surface of the penetrating cerebral arterioles.
Mechanism of the Effect of Adenosine on EAA Transport
The excitatory neurotransmitters aspartate and glutamate are abundant amino acids in the mammalian brain and in brain endothelial cells, and are carried by the same transporter system. 3 Although glutamate is present in large amounts in the brain, almost all brain glutamate is stored intracellularly against a concentration gradient. Therefore, the extracellular glutamate concentration is normally low. The regulation of extracellular glutamate and aspartate levels is achieved by a high-affinity reuptake system located on neurons, glia, and on the BBB. 7, 18, 24 Brain glutamate and aspartate concentrations are determined by the relative influx, efflux, and metabolism (that is, L-glutamine and L-asparagine, respectively), and by cell membrane depolarization. Whereas several amino acids are transported into the brain, glutamate and aspartate have little access to the brain from the blood, and there is evidence for a net efflux of both amino acids under physiological conditions. 17 During ischemia, however, the capacity to clear extracellular aspartate and glutamate can be severely reduced. 26 The abluminal membrane of endothelial cells expresses a highaffinity concentrative and Na ϩ -dependent transport system for glutamate and aspartate. Three high-affinity Na ϩ -dependent transporters have been characterized on the abluminal membrane of brain endothelial cells and are designated EAAT1 (GLAST), EAAT2 (GLT-1), and EAAT3 (EAAC1); 24 in addition, EAAT1, EAAT4, and EAAT5 have been cloned as EAA transporters, the first two in the cerebellum and the last in the retina, and play a role in the maintenance of extracellular EAA concentrations below neurotoxic levels. 16 In contrast, at the luminal membrane, a low-capacity and Na ϩ -independent carrier has been described. 2, 12, 30 This glutamate/aspartate carrier is greater than 80% saturated at normal plasma concentrations, and measurements of glutamate transport across the BBB, made using the intracarotid injection technique of Oldendorf and Szabo, 25 have confirmed only a slow influx of glutamate into the brain. The BBB transport constant (Km or half-saturation concentration in the absence of competitors), as measured by the in situ ratperfusion technique, is 101 mol/L for aspartate uptake into the brain and 24 mol/L for glutamate uptake. These rate constants reflect the brain's ability to synthesize L-glutamate and L-aspartate. 13 In addition, D-aspartate can be synthesized in the brain and its excessive accumulation has been related to Alzheimer disease and the aged brain. 9 Therefore, what is important for the fate of glutamate and aspartate under normal physiological conditions is not their influx into the brain, but their efflux. 2 In the present study, we have demonstrated that abluminal adenosine at physiological concentrations (10 Ϫ7 M) decreases the net extravasation of both glutamate and aspartate into the brain. Consequently, we hypothesize that adenosine is acting on the high-affinity abluminal transporters of EAA and not on the low-affinity luminal uptake system (Fig. 7) . The data provided earlier also show that theophylline, an adenosine receptor blocker, attenuates the adenosine-mediated effect on EAA transport, which indicates that the effect of adenosine on EAA transport is receptor mediated. A possible physiological role for adenosine's modulation of transport would be to remove excessive EAA from the brain interstitial fluid.
Although this is the first report of EAA transport regulation in endothelial cells, on the basis of rapidly accumulating data we can infer that the expression of EAA transporters in neurons and astrocytes is also amenable to regulation by different pharmacological agents and naturally occurring substances, such as NO, amyloid ␤ peptide, N-methyl-D-aspartate receptor antagonists, free O 2 radicals, cyclic adenosine monophosphate, and cyclic guanosine monophosphate.
10,16
Conclusions
We have demonstrated that physiological concentrations of adenosine, a known regulator of CBF and a neuroprotectant, can modulate EAA transport across the BBB. In an isolated blood vessel preparation, adenosine decreased the net extravasation of aspartate and glutamate into the brain,
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Glutamate, aspartate, adenosine, and the blood-brain barrier 559 FIG. 7. Schematic representation of EAA transport at the BBB. The Na ϩ -dependent EAA transporters for glutamate (Glu) and aspartate (Asp) exist on the abluminal surface. Low-affinity transporters exist on the luminal surface. We propose that adenosine acts abluminally via an adenosine receptor to modulate EAA transport.
although it did not alter the BBB integrity in response to sucrose. The blockade of adenosine's effect on EAA transport by theophylline indicates that this action is a receptormediated event. Further characterization of this novel effect of adenosine on the modulation of EAA transport across the BBB may lead to the development of novel therapeutic strategies for use in brain ischemia and an understanding of the role of the BBB during pathological states.
